<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - DEXAMETHASONE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>DEXAMETHASONE</h1>

        <p><a href="../drugClass/PHP34623.html">CORTICOSTEROIDS (SYSTEMIC)</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Suppression of inflammatory and allergic disorders</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.5&#8211;10 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Local treatment of inflammation (short term)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially to the eye using eye drop</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply every 30&#8211;60 minutes until controlled, then (to the eye) reduced to 4&#8211;6 times a day.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Apply 4&#8211;6 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Short term local treatment of inflammation (severe conditions)</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye using eye drop</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children </strong><br/>
                Apply every 30&#8211;60 minutes until controlled, reduce frequency when control achieved.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Macular oedema following either branch retinal vein occlusion or central retinal vein occlusion (specialist use only)</span>,
                <span class="indication">Visual impairment due to diabetic macular oedema in adults who are pseudophakic, or who are insufficiently responsive to, or unsuitable for non-corticosteroid therapy (specialist use only)</span>,
                <span class="indication">For the treatment of inflammation of the posterior segment of the eye presenting as non-infectious uveitis (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                700 micrograms, to be administered into the affected eye, concurrent administration to both eyes not recommended. For further information on pre-treatment, administration and repeat dosing, consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mild croup</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 micrograms/kg for 1 dose.</li>
              <li class="dose child"><strong>For children </strong><br/>
                150 micrograms/kg for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe croup (or mild croup that might cause complications)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 150 micrograms/kg for 1 dose, to be given before transfer to hospital, then (by mouth or by intravenous injection) 150 micrograms/kg, then (by mouth or by intravenous injection) 150 micrograms/kg after 12 hours if required.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Initially 150 micrograms/kg for 1 dose, to be given before transfer to hospital, then (by mouth or by intravenous injection) 150 micrograms/kg, then (by mouth or by intravenous injection) 150 micrograms/kg after 12 hours if required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diagnosis of Cushing&#8217;s disease</span>,
                <span class="indication">Congenital adrenal hyperplasia</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.5&#8211;10 mg daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                0.4&#8211;20 mg.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Overnight dexamethasone supression test</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 mg for 1 dose, to be given at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive treatment of bacterial meningitis (starting before or with first dose of antibacterial)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                8.3 mg every 6 hours for 4 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Symptom control of anorexia (in palliative care)</span>,
            </h4>
            <p class="specificity"><span class="route"></span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2&#8211;4 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Obstruction due to tumour (dysphagia in palliative care)</span>,
            </h4>
            <p class="specificity"><span class="route"></span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                8 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bronchospasm or partial obstruction (dyspnoea in palliative care)</span>,
            </h4>
            <p class="specificity"><span class="route"></span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                4&#8211;8 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nausea and vomiting (adjunct in palliative care)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                8&#8211;16 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Headaches due to raised intracranial pressure (in palliative care)</span>,
            </h4>
            <p class="specificity"><span class="route"></span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                16 mg daily for 4&#8211;5 days, then reduced to 4&#8211;6 mg daily, reduce dose if possible. To be given before 6pm to reduce the risk of insomnia.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain due to nerve compression (in palliative care)</span>,
            </h4>
            <p class="specificity"><span class="route"></span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                8 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cerebral oedema associated with malignancy</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.5&#8211;10 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cerebral oedema (with dexamethasone as sodium phosphate 3.8&#8239;mg/mL injection)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 8&#8211;16 mg, then (by intramuscular injection or by intravenous injection) 5 mg every 6 hours until adequate response achieved then taper-off gradually.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cerebral oedema associated with malignancy (with dexamethasone as sodium phosphate 3.3&#8239;mg/mL injection)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 8.3 mg, then (by intramuscular injection) 3.3 mg every 6 hours as required for 2&#8211;4 days, subsequently, reduce dose gradually and stop over 5&#8211;7 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Local inflammation of joints (with dexamethasone as sodium phosphate 3.8&#8239;mg/mL injection)</span>,
            </h4>
            <p class="specificity"><span class="route">By intra-articular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.3&#8211;3 mg, dose given according to size, where appropriate may be repeated at intervals of 3&#8211;21 days according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Local inflammation of joints (with dexamethasone as sodium phosphate 3.3&#8239;mg/mL injection)</span>,
            </h4>
            <p class="specificity"><span class="route">By intra-articular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.33&#8211;3.3 mg, dose given according to size, where appropriate may be repeated at intervals of 3&#8211;21 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Local inflammation of soft tissues (with dexamethasone as sodium phosphate 3.3&#8239;mg/mL injection)</span>,
            </h4>
            <p class="specificity"><span class="route">By local infiltration</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.7&#8211;5 mg, dose given according to size, where appropriate may be repeated at intervals of 3&#8211;21 days.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravitreal</ph> use in adults</h3>
              <p>Manufacturer advises avoid unless potential benefit outweighs risk&#8212;no information available.</p>
            </section>
            <section class="generalInformation">
              <p>Dexamethasone readily crosses the placenta.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>uncommon:</strong> eyelid pruritus in adults, glaucoma in adults, migraine in adults, necrotising retinitis in adults,
              </p>
              <p>
                <strong>notKnown:</strong> local sensitivity reactions, adrenal suppression following prolonged use in neonates in neonates, corneal thinning, scleral thinning, perineal irritation may follow intravenous administration of the phosphate ester, blepharitis in adults, cataract in adults, headache in adults, ocular hypertension in adults, raised intra-ocular pressure in adults, secondary ocular infection in adults, visual disturbance in adults,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>For administration <i>by mouth</i> tablets may be dispersed in water or injection solution given by mouth.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i> dilute with Glucose 5% or Sodium Chloride 0.9%; give over 15&#8211;20 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Dexamethasone</i>, Hospira) give continuously <i>or</i> intermittently <i>or via</i> drip tubing <i>in</i> Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Patient counselling is advised for dexamethasone tablet, oral solution and injection (steroid card).</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Dexamethasone for croup</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/dexamethasone-croup-0">www.medicinesforchildren.org.uk/dexamethasone-croup-0</xref>
            </p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA229</h3>
              <p outputclass="specificity">With <ph outputclass="route">intravitreal</ph> use in adults</p> <p outputclass="title">Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (July 2011)</p> <p>Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following central retinal vein occlusion.</p> <p>Dexamethasone intravitreal implant is also recommended as an option for the treatment of macular oedema following branch retinal vein occlusion when:</p> <ul> <li>treatment with laser photocoagulation has not been beneficial, <i>or</i> </li> <li>treatment with laser photocoagulation is not considered suitable because of the extent of macular haemorrhage.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA229">www.nice.org.uk/TA229</xref>
                <a href="http://www.nice.org.uk/TA229" target="_blank">www.nice.org.uk/TA229</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by ear:</strong>
            avoid prolonged use
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            history of ocular viral infection (including herpes simplex) in adults
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            posterior capsule tear or iris defect (risk of implant migration into the anterior chamber which may cause corneal oedema and, in persistent severe cases, the need for corneal transplantation) in adults
          </li>
          <li>
              <strong>With intravitreal use:</strong>
            retinal vein occlusion with significant retinal ischaemia in adults
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravitreal</ph> use in adults</h3>
              <p>Monitor intra-ocular pressure and for signs of ocular infection. In patients with posterior capsule tear or iris defect monitor for implant migration to allow for; early diagnosis and management.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Consult product literature; not licensed for use in bacterial meningitis.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph> in children</h3>
              <p>
            <i>Maxidex</i>
            <tm tmtype="reg"/> not licensed for use in children under 2 years.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph> in children</h3>
              <p>
            <i>Dropodex</i>
            <tm tmtype="reg"/> not licensed for use in children.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Dexamethasone 3.8&#8239;mg/mL Injection has replaced Dexamethasone 4&#8239;mg/mL Injection.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Although multi-dose Dexamethasone eye drops commonly contain preservatives, preservative-free unit dose vials may be available.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of DEXAMETHASONE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            eye drops,
            oral suspension,
            oral solution,
            capsule,

            <div id="PHP75668"><a href="../medicinalForm/PHP75668.html" data-target="#PHP75668" data-action="load">Tablet</a></div>
            <div id="PHP75717"><a href="../medicinalForm/PHP75717.html" data-target="#PHP75717" data-action="load">Oral solution</a></div>
            <div id="PHP75704"><a href="../medicinalForm/PHP75704.html" data-target="#PHP75704" data-action="load">Solution for injection</a></div>
            <div id="PHP75710"><a href="../medicinalForm/PHP75710.html" data-target="#PHP75710" data-action="load">Eye drops</a></div>
            <div id="PHP75696"><a href="../medicinalForm/PHP75696.html" data-target="#PHP75696" data-action="load">Implant</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
